NOVONORDISK TURKEY

Novo Nordisk Turkey is a subsidiary of Novo Nordisk, a global healthcare company headquartered in Denmark, which is focused on the research, development, production, and distribution of diabetes care products, as well as hemophilia care, growth hormone therapy, and hormone replacement therapy.

The Turkish subsidiary of Novo Nordisk was established in 1987 and has since then become a prominent player in the Turkish pharmaceutical market. The company has a strong presence in Turkey with offices in Istanbul, Ankara, and Izmir. Novo Nordisk Turkey employs more than 200 people who work tirelessly to ensure that the company’s mission of improving the lives of people living with diabetes is achieved.

Novo Nordisk Turkey’s portfolio of products includes insulin, oral antidiabetic drugs, and devices for diabetes management. The company’s insulin portfolio covers a broad range of products from rapid-acting to long-acting insulin, including insulin pens and pumps. These products are designed to meet the needs of different patient groups, from children to adults, and from those with type 1 diabetes to those with type 2 diabetes.

Novo Nordisk Turkey is committed to improving the lives of people living with diabetes by providing them with the tools they need to manage their condition effectively. The company does this through various patient support programs, including diabetes education programs and patient helplines. The company also organizes events and seminars for healthcare professionals to enhance their knowledge of diabetes care.

In addition to its diabetes care products and services, Novo Nordisk Turkey also offers products for the treatment of hemophilia, a rare bleeding disorder. The company’s hemophilia portfolio includes recombinant clotting factors and factor VIII inhibitors.

Novo Nordisk Turkey is committed to ensuring that its products are available to all those who need them. To achieve this, the company works with healthcare providers, insurance companies, and patient organizations to make its products accessible and affordable to patients. The company also partners with the Turkish Ministry of Health to improve the quality of diabetes care in the country.

Novo Nordisk Turkey is also committed to sustainability and social responsibility. The company has a strong focus on reducing its environmental impact and has implemented various initiatives to achieve this, such as reducing greenhouse gas emissions and improving waste management. The company is also involved in various social responsibility initiatives, such as supporting education and healthcare programs in underprivileged communities.

In conclusion, Novo Nordisk Turkey is a leading player in the Turkish pharmaceutical market, with a strong focus on improving the lives of people living with diabetes and other chronic conditions. The company’s commitment to innovation, patient support, and social responsibility has earned it a reputation as a reliable and responsible healthcare partner in Turkey. With its portfolio of diabetes care products and services, Novo Nordisk Turkey is well-positioned to continue its mission of improving the lives of people living with diabetes in Turkey and beyond.